Chidamide (Epidaza) is an histone deacetylase inhibitor (HDI) developed wholly in China. It was also known as HBI-8000. It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10.
Chidamide is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL), and has orphan drug status in Japan. As of April 2015 it is only approved in China.
Chidamide is being researched as a treatment for pancreatic cancer. However, it is not FDA approved for the treatment of pancreatic cancer.
